Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye size may reveal which kids benefit most from myopia lenses

NCT ID NCT07808047

Disease control Sponsor: Bambino Gesù Hospital and Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests whether pupil size changes can predict how well peripheral defocus spectacle lenses slow myopia progression in children. Researchers will measure pupil responses and track eye growth over 24 months in 14 kids with progressive myopia. The goal is to see if a simple pupil test could help personalize myopia treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Peripheral defocus spectacle lenses
What this could lead to
If pupil size predicts lens effectiveness, doctors could personalize myopia control for children, improving outcomes.
What could go wrong
This is a small, early study with only 14 children. It may not find a clear link, and results may not apply to all kids with myopia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

primary care clinic

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: progressive myopia Exclusion Criteria: suspected genetic syndromes all systemic or eye diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia progressing are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia progressing

Contacts and locations

Locations

  • Luca Buzzonetti

    Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.